Abstract
Synopsis: Many patients at risk of coronary events fail to achieve recommended LDL-C goals with statin monotherapy and are therefore at increased risk of future coronary events. This study evaluated efficacy of switching hypercholesterolemic patients at high cardiovascular risk who failed to achieve adequate lowering of LDL-C with prior statin monotherapy to ezetimibe/simvastatin (EZE/SIMVA) versus rosuvastatin (ROSUVA).
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call